Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurological disorders
Pharma
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Cobenfy, a key component in BMS’ plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback in schizophrenia.
Angus Liu
Apr 23, 2025 10:35am
Neurology patients call out pharma for inadequate investment
Nov 19, 2024 11:20am
Neurocrine elevates BD chief to succeed founder and CEO
May 29, 2024 11:42am
Neurocrine joins in on Tardive Dyskinesia Awareness Week
May 6, 2024 10:52am
AZ's Alexion debuts short film highlighting NMOSD community
Apr 18, 2024 2:16pm
FDA expands AZ's Ultomiris to NMOSD after prior rejection
Mar 25, 2024 10:31am
